NRS
PTPI

Neville Rodie & Shaw’s Petros Pharmaceuticals PTPI Stock Holding History

Neville Rodie & Shaw’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-88
Closed -$44K – 267
2021
Q3 		$44K Hold
88
– – ﹤0.01% 257
2021
Q2 		$68K Hold
88
– – 0.01% 259
2021
Q1 		$82K Hold
88
– – 0.01% 254
2020
Q4 		$96K Buy
+88
New +$82.8K 0.01% 250

Other funds holding PTPI

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Neville Rodie & Shaw's PTPI Position: Q4 2021 in Review

Neville Rodie & Shaw sold out of Petros Pharmaceuticals (PTPI) in Q4 2021, closing a stake of 88 shares — an estimated $44K sold.

Neville Rodie & Shaw first reported a position in PTPI in Q4 2020 and held it in 4 quarters. The position peaked at $96K in Q4 2020. 18 funds tracked by Wall St. Rank hold PTPI as of Q4 2021.

  • Neville Rodie & Shaw reported no remaining Petros Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Neville Rodie & Shaw sold 88 Petros Pharmaceuticals shares in Q4 2021, an estimated $44K.
  • Neville Rodie & Shaw first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Neville Rodie & Shaw's Petros Pharmaceuticals position peaked at $96K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q4 2021.

Based on Neville Rodie & Shaw's 13F filing for Q4 2021, filed 5 Jan 2022.